GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Accolade Inc (NAS:ACCD) » Definitions » Net Current Asset Value

Accolade (Accolade) Net Current Asset Value : $-1.02 (As of Nov. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Accolade Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Accolade's net current asset value per share for the quarter that ended in Nov. 2023 was $-1.02.

The historical rank and industry rank for Accolade's Net Current Asset Value or its related term are showing as below:

During the past 6 years, the highest Price-to-Net-Current-Asset-Value Ratio of Accolade was 9.86. The lowest was 6.68. And the median was 7.84.

ACCD's Price-to-Net-Current-Asset-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 6.63
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Accolade Net Current Asset Value Historical Data

The historical data trend for Accolade's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accolade Net Current Asset Value Chart

Accolade Annual Data
Trend Feb18 Feb19 Feb20 Feb21 Feb22 Feb23
Net Current Asset Value
Get a 7-Day Free Trial -7.20 -6.03 6.63 -0.31 -0.87

Accolade Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.85 -0.87 -0.97 -1.06 -1.02

Competitive Comparison of Accolade's Net Current Asset Value

For the Health Information Services subindustry, Accolade's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accolade's Price-to-Net-Current-Asset-Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Accolade's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Accolade's Price-to-Net-Current-Asset-Value falls into.



Accolade Net Current Asset Value Calculation

Accolade's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Feb. 2023 is calculated as

Net Current Asset Value Per Share(A: Feb. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(365.949-429.283-0-0)/73.0891
=-0.87

Accolade's Net Current Asset Value (NCAV) per share for the quarter that ended in Nov. 2023 is calculated as

Net Current Asset Value Per Share(Q: Nov. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(272.09-350.752-0-0)/76.9664
=-1.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accolade  (NAS:ACCD) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Accolade Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Accolade's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Accolade (Accolade) Business Description

Traded in Other Exchanges
Address
1201 Third Avenue, Suite 1700, Seattle, WA, USA, 98101
Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. It generates revenue by providing personalized health guidance solutions to members.
Executives
Richard Eskew officer: EVP General Counsel C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Stephen H. Barnes officer: Chief Financial Officer C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Rajeev Singh director, officer: Chief Executive Officer 6222 185TH AVENUE NE, REDMOND WA 98052
Robert N Cavanaugh officer: President 1601 CLOVERFIELD BLVD., SUITE 620, SANTA MONICA CA 90404
Mchugh Colin officer: Chief Accounting Officer C/O ACCOLADE, INC., 660 W. GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Michael W Hilton officer: Chief Product Officer 6222 185TH AVE, REDMOND WA 98052
Peter S Klein director C/O MICROSOFT CORPORATION, ONE MICROSOFT WAY, REDMOND WA 98052-6399
Cindy Kent director 7601 PENN AVENUE SOUTH, RICHFIELD MN 55418
Patricia L Wadors director C/O ALIGN TECHNOLOGY INC, 881 MARTIN AVE, SANTA CLARA CA 95050
Dawn G Lepore director 1425 BROADWAY PMB 41, SEATTLE WA 99122
Jeffrey D Jordan director 2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
Jeffrey S Brodsky director C/O MORGAN STANLEY 1585 BROADWAY, NEW YORK NY 10036
Thomas J Neff director SPENCER STUART & ASSOCIATES, 277 PARK AVE, NEW YORK NY 10172
William H. Frist director 600 MONTGOMERY STREET, SAN FRANCISCO CA 94111